NeuroOne Medical Technologies Corp. Appoints Vanessa Tolosa To Scientific Advisory Board: Leading Researcher In Neurotech To Guide Further Development Of Thin-film Electrodes

NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Vanessa Tolosa...
Author:
Publish date:

NeuroOne Medical Technologies Corporation (OTCQB: NMTC; NeuroOne), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, announces today the appointment of Vanessa Tolosa to its Scientific Advisory Board. Tolosa, one of the founding members of Neuralink Corp., a company started by Elon Musk to build a complete Brain-Machine Interface, brings specialized expertise that the company believes will help expedite its further development of thin-film electrodes that provide long-term stimulation for treatment of neurological applications, such as epilepsy, Parkinson's disease, failed back surgery syndrome and other neurological applications that may benefit from high-density thin film electrode technology.

"We are pleased to have such a distinguished, highly regarded scientific leader and pioneer as Vanessa on our advisory board," says Dave Rosa, president and CEO, NeuroOne. "Vanessa has over 10 years of specialized experience developing implantable neural devices. She shares our passion in transitioning these technologies from the bench top and bringing them to patients who are in desperate need. Her exceptional experience in this field will contribute greatly to NeuroOne's vision, goals and future direction."

Most recently at Neuralink, Tolosa worked to develop a Brain Machine Interface for medical use and beyond. As director of neural interfaces, she directed the design, prototyping, development and testing of technologies related to implantable microelectrodes, electronics micro-assembly and hermetic packaging. Previously, at Lawrence Livermore National Laboratories (LLNL), Tolosa led all implantable neurotechnology efforts, including high-density electrode technology.

Among her credits, Tolosa won the 2019 Gold Electrode Researcher of the Year Award from Neurotech Reports, the 2015 LLNL Early-Mid Career Researcher Award and the 2015 DARPA Riser Award. She holds eight issued patents with five pending applications in this field. Tolosa earned a B.S. in Chemical Engineering from the University of Florida and a Ph.D. in Chemical Engineering from the University of California, Los Angeles.

Tolosa states, "NeuroOne is bringing unique thin-film electrodes to the marketplace, and I look forward to helping them refine their implantable neural technology that addresses chronic treatments, as well as making enhancements to its FDA-cleared Evo cortical electrode line."

About NeuroOne

NeuroOne Medical Technologies Corporation is a developmental stage company committed to providing minimally invasive and hi-definition solutions for EEG recording, brain stimulation and ablation solutions for patients suffering from epilepsy, Parkinson's disease, essential tremors and other related neurological disorders that may improve patient outcomes and reduce procedural costs. Visit https://www.n1mtc.com/.

Forward Looking Statements

This press release may include forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this presentation may be a forward‐looking statement that reflects the Company's current views about future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. In some cases, you can identify forward‐looking statements by the words "may," "might," "will," "could," "would," "should," "expect," "intend," "plan," "objective," "anticipate," "believe," "estimate," "predict," "project," "potential," "target," "seek," "contemplate," "continue" and "ongoing," or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward‐looking statements may include statements regarding the Company's regulatory submissions, potential regulatory approval, commercialization of the technology, business strategy, market size, potential growth opportunities, plans for product applications and product development, future operations, future efficiencies, and other financial and operating information. Although the Company believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain. Our actual future results may be materially different from what we expect due to factors largely outside our control, including our ability to raise additional funds, uncertainties inherent in the development process of our technology, changes in regulatory requirements or decisions of regulatory authorities, the size and growth potential of the markets for our technology, our ability to serve those markets, the rate and degree of market acceptance of our products, clinical trial patient enrollment, the results of clinical trials, future competition, the actions of third-party clinical research organizations, suppliers and manufacturers, our ability to protect our intellectual property rights and other risks, uncertainties and assumptions, including those described under the heading "Risk Factors" in our filings with the Securities and Exchange Commission. These forward‐looking statements speak only as of the date of this press release and the Company undertakes no obligation to revise or update any forward‐looking statements for any reason, even if new information becomes available in the future.

"Caution: Federal law restricts this device to sale by or on the order of a physician"

View source version on businesswire.com: https://www.businesswire.com/news/home/20200428005038/en/